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Background.  – Gross  total  or near  total resection  (GTR/NTR;  resection  ≥ 95%)  of glioblastoma  (GBM)  seems
correlated  with  a longer  survival.  Intraoperative  MRI  (ioMRI)  is  one  method  to  evaluate  the  extent  of
resection  (EOR)  in  order  to improve  it during  the same  anesthesia.  We  compared  GBM  resections  using  a
3.0T  ioMRI  and then  without  considering  the  EOR,  safety,  survival  and  discussed  the  indications  for  using
this  expensive  modality.
Methods. – Between  March  2006  and  November  2011,  56  GBM  resections  were  performed  using  an  ioMRI,
and  38 without  (control  group).  The  only  criterion  in order to  have  access  to the  ioMRI  was  its availability.
We  compared  the  variables  EOR,  Karnofsky  Performance  Scale  scores  and  survival  in both  groups.
Results. – In the ioMRI  group,  15  patients  (26.8%)  underwent  an immediate  second  resection  increasing
the  GTR  rate  of 10.7%  and the  GTR/NTR  rate of  8.9%.  There  was  a signiﬁcant  difference  between  the  use
of  an  ioMRI  and  the  control  group  in reaching  a  larger  EOR  (P = 0.049,  Fisher’s  exact  test).  The effect
of  using  the  ioMRI  or  not  on the  overall  survival,  with EOR  as  covariate,  was  not signiﬁcant  (P = 0.147,
Likelihood  ratio  test).  However,  the  EOR  alone  had  a signiﬁcant  effect  on  survival  (P =  0.049,  Wald  test),
with  a shorter  survival  for the  patients  with  a partial  resection  (PR)  than  a  GTR/NTR  (Hazard  ratio  =  1.6,
95%  CI HR:  1.00–2.69),  with  a median  overall survival  of  15.26  months  (95%  CI:  12.34–19.08)  for  the
GTR/NTR  subgroup  versus  10.26  months  (95%  CI: 6.64–15.82)  for the  PR  subgroup.  Multivariate  regression
analysis  also  identiﬁed  age, sex  and  adjuvant  chemotherapy  as factors  signiﬁcantly  associated  with  overall
survival.
Conclusions.  – A  3.0T  ioMRI  improved  the  quality  of  resection  by 17.8%  and  increased  the  GTR/NTR  rate  by
8.9%  up to  73.2%  without  additional  morbidity.  A GTR/NTR  improves  survival  duration  by  about  50%.  Thus,
it  remains  reasonable  to increase  the  EOR  to reach  GTR/NTR  using  an intraoperative  control.  However,
ioMRI  should  be limited  to the  cases  for which  a GTR/NTR  seems  preoperatively  possible.
©  2014  Elsevier  Masson  SAS.  
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Description  et objectif.  – Une  résection  totale  ou quasi-totale  (GTR/NTR)  (≥ 95  %)  du  glioblastome  (GBM)
semble  corrélée  à une  survie  plus  longue.  L’IRM  per-opératoire  (ioMRI)  est une  méthode  pour  évaluer
l’étendue  de résection  (EOR)  dans  le  but de  l’améliorer.  Nous  avons  comparé  la chirurgie  des  GBM  avec
et  sans  ioMRI  3.0T  en  fonction  de  l’EOR,  la  sûreté  et  discuté  les  indications  de  cette  modalité  coûteuse.
Méthodes. – Entre  mars  2006  et  novembre  2011,  56 glioblastomes  ont  été  réséqués  à  l’aide  d’une  ioMRI  et
38  sans  ioMRI  (groupe  témoin).  Le  seul  critère  d’accès  à l’ioMRI  était  sa disponibilité.  Nous  avons  comparé
les  variables  EOR,  scores  de  Karnofsky  Performance  Scale  et  la  survie  dans  les  deux groupes.
∗ Corresponding author.
E-mail address: christian.raftopoulos@uclouvain.be (C. Raftopoulos).
http://dx.doi.org/10.1016/j.neuchi.2014.03.010
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Résultats.  – Dans  le  groupe  ioMRI,  15  patients  (26,8  %)  ont  bénéﬁcié  d’une  ré-intervention  immédiate  aﬁn
d’étendre la résection,  augmentant  le taux  de  GTR  de 10,7  % et  GTR/NTR  de  8,9 %. Il y a  un  lien signiﬁcatif
entre l’utilisation  de l’ioMRI  et  une  EOR  plus  élevée  (p = 0,049,  test  exact  de  Fisher).  L’effet  de l’utilisation
ou non  de  l’ioMRI  sur  la survie,  avec  l’EOR  comme  covariable,  n’est  pas  signiﬁcatif  (p  = 0,147,  Likelihood
ratio test).  Cependant,  la  variable  EOR  seule  a un  effet  signiﬁcatif  sur  la  survie  (p  = 0,049,  Wald  test),
avec une  survie  plus  courte  pour  les  patients  avec  une  résection  partielle  (PR)  que  pour  les  patients
avec GTR/NTR  (Hazard  ratio  = 1,6,  IC 95%  HR  :  1,00–2,69).  La survie  médiane  est  de  15,26  mois  (IC  95%  :
12,34–19,08) pour  le groupe  GTR/NTR  versus  10,26  mois  (IC 95%  : 6,64–15,82)  pour le  groupe  PR.  L’analyse
par régression  multivariée  a aussi  identiﬁé  que l’âge,  le sexe  et la  chimiothérapie  adjuvante  étaient  des
facteurs signiﬁcativement  associés  à  la  survie.
Conclusions. – Une ioMRI  à 3.0T  augmente  la  qualité  de  la  résection  de  17,8  % et améliore  le  taux  de
GTR/NTR de  8,9  %, sans  morbidité  supplémentaire.  Une  EOR  ≥  95 % augmente  la  survie  d’environ  50  %. Il
apparaît raisonnable  d’augmenter  l’EOR  à l’aide  d’un  contrôle  per-opératoire.  Cependant,  l’ioMRI  devrait
être limitée  aux  cas  pour  lesquels  une  GTR/NTR  semble  possible  en  préopératoire.
©  2014  Elsevier  Masson  SAS. Tous  droits  réservés.
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Fig. 1. Extent of resection of 56 GBM operated on using ioMRI control (%): using
ioMRI increased the rate of GTR/NTR of 8.9%. GBM: glioblastoma; GTR: gross total
resection; ioMRI: intraoperative MRI; NTR: near total resection; p-op: postopera-
tive;  PR: partial resection.
Étendue  de résection de 56 GBM opérés avec un contrôle ioMRI (%): utiliser l’ioMRI aug-. Introduction
Despite advances in oncology therapies and surgical techniques,
 glioblastoma multiforme (GBM) (WHO grade IV) remains associ-
ted with a poor prognosis, and a median survival of approximately
ne year [1–5].
The  standard treatment is maximized surgical resection, fol-
owed by radio-chemotherapy [6]. However, the value of surgery
or GBM remains altered by confounding variables inﬂuencing
urvival (tumor location, age, performance status, combined treat-
ents) [1–4,7–11]. Although some authors consider that surgery as
 treatment for GBM remains poor to signiﬁcantly prolong patients’
ife [12,13], there seems to be a consensus regarding the necessity
f reaching GTR/NTR for signiﬁcantly improving patient survival
2–4,8–11,14,15].
Different modern technologies help neurosurgeons to obtain a
ross total or near total resection GTR/NTR of the tumor when-
ver possible. Intraoperative MRI  (ioMRI) permits to improve the
umor resection if possible [14–16]. ioMRI allows to update the
reoperative images in real-time, to quantify the tumor residue if
resent, and pursue the resection when appropriate. It has been
hown that using ioMRI signiﬁcantly increases the GTR rate of
BM [8,11,14,16–24]. The extent of resection (EOR), which can be
mproved by ioMRI, is signiﬁcantly linked to the survival duration
f patients suffering from GBM [8,11,13–15]. Despite this sub-
tantial advantage, the impact of ioMRI on surgery in terms of
osts and time loss has also been highlighted by several authors
14,18,25–29].
Few teams have reported the experience of brain surgery using a
.0T ioMRI procedure [25,30]. The aim of our study was  to compare
BM surgery using a 3.0T ioMRI and without it. We  analyzed the
OR, the survival, the impact and safety of a 3.0T ioMRI as well as
he indications for using this type of procedure.
. Material and method
.1.  Population
Ninety-four patients diagnosed with GBM were operated on
rom March 2006 to November 2011 in our department. Fifty-six
atients were operated using a 3.0T ioMRI, solely on the basis of
ccessibility and not on the possibility of reaching a GTR, and 38
atients underwent surgery without using a 3.0T ioMRI constitut-
ng the control group..2.  Method
All  the interventions were performed under computer-assisted
avigation (BrainLab, Germany) based on a MRI  performed the daymente le taux de GTR/NTR de 8,9 %. GBM : glioblastome ; GTR : résection totale ; ioMRI :
IRM intra-opératoire ; NTR : résection quasi-totale ; p-op : postopératoire ; PR : résection
partielle.
before surgery. The ioMRI was  performed using a 3.0 Tesla MRI
Philips Achieva system. We installed this machine in our hospital
in 2006, in a dedicated operating room next to the main oper-
ating room, forming a twin operating room-magnetic resonance
imaging suite [26]. After resection and based on the surgeon’s
assessment, the operating ﬁeld was  closed either partially (if an
additional resection was likely) or completely (if no additional
resection seemed probable). Regarding the ioMRI, the senior neu-
roradiologist with the senior neurosurgeon quantiﬁed the extent of
resection by contouring the tumor on post-gadolinium T1 images
pre and per-operatively to obtain a preoperative and per-operative
volume in order to permit a resection percentage assessment. If a
tumor residue remained, the surgeon could decide either to con-
tinue the resection in order to maximize it or to stop the surgical
procedure. These per-operative observations were prospectively
collected. The patients who  had an additional resection also had
a postoperative MRI  within the following 48 hours (Fig. 1).2.3. Variables and statistics
GTR  was deﬁned as no visible tumor residue. NTR was charac-
terized by a residue ≤ 5% and a partial resection (PR) included a
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Table  1
Distribution of patients’ characteristics between the 4 subgroups.
Distribution  des caractéristiques des patients entre les 4 sous-groupes.
All patients ioMRI No ioMRI P-value
GTR/NTR
(Re ≤ 5%)
PR
(Re > 5%)
GTR/NTR
(Re ≤ 5%)
PR
(Re > 5%)
Effectives (%) 94 41 (73) 15 (27) 20 (52) 18 (48) 0.049d
Age (years) 0.243e
Mean 59.9 59.1 55.2 64.6 60.2
Standard  deviation 13.75 12.90 20.57 10.45 11.18
Median  61.4 61.4 55.7 65.5 60.3
Minimum–Maximum 14–82 19–79 14–82 42–80 41–81
Sex  (%)
Female 39 (41.5) 16 5 10 8 0.759f
Male 55 (58.5) 25 10 10 10
Tumor  side (%)
Left  43 (45.7) 16 9 9 9 0.643f
Right 49 (52.1) 23 6 11 9
Missing  2 (2.1) 2 0 0 0
Location  (%) 0.375f
Frontal 16 (17.0) 7 1 6 2
Temporal  28 (29.8) 14 6 4 4
Parietal  15 (16.0) 8 1 3 3
Occipital  3 (3.2) 3 0 0 0
Elsewherea 31 (33.0) 8 7 7 9
Missing  1 (1.1) 1 0 0 0
Karnofsky  score (%)
Preoperativeb 0.073f
0–50 5 (5.3) 0 1 1 3
60–100  89 (94.7) 41 14 19 15
Postoperativec 0.085f
0–50 17 (18.1) 5 5 4 3
60–100  75 (79.8) 36 10 14 15
Missing  2 (2.1) 0 0 2 0
Shift  from preoperative score 0.330f
Increase 92 41 15 18 18
Stable  −5.8 6.3 −1.1 5 1.1
Decrease  15.5 15.2 22.5 10.4 12.8
Missing  0 0 0 0 0
Concomitant chemotherapy 0.328f
Yes 68 (72.3) 32 8 15 13
No  26 (27.7) 9 7 5 5
Concomitant radiotherapy 0.344f
Yes 77 (81.9) 35 10 16 16
No  17 (18.1) 6 5 4 2
Adjuvant  chemotherapy 0.260f
Yes 60 (63.8) 30 7 13 10
No  34 (36.2) 11 8 7 8
GTR: gross total resection; F: female; L: left; M:  male; NTR: near total resection; PR: partial resection; Re: residue; R: right.
GTR : résection totale ; F : femme ; L : gauche ; M : homme ; NTR : résection quasi-totale ; PR : résection partielle ; Re : résidu ; R : droite.
a Including temporo-parietal, parieto-frontal, parieto-occipital, temporo-insular, temporo-occipital, thalamic, intraventricular, bifrontal, hippocampic, fronto-parietal,
fronto-insular, fronto-temporal, trigone, frontal-intravent fronto-temporo-in.
a Comprenant temporo-pariétal, pariéto-frontal, pariéto-occipital, temporo-insulaire, temporo-occipital, thalamique, intraventriculaire, bifrontal, hippocampique, fronto-parietal,
fronto-insular, fronto-temporal, carrefour, frontal-intravent fronto-temporo-in.
b Scores (%) before surgery.
b Scores (%) avant chirurgie.
c Scores (%) before discharge.
c Scores (%) avant la sortie de l’hôpital.
d Fisher exact test.
d Test exact de Fisher.
e ANOVA.
e Anova.
f Chi2 test.
f
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tTest de Chi2 .
esidue > 5%. As the reported literature has shown that GTR/NTR
akes a difference in survival duration [3,8,9,14,17], two groups
ere deﬁned by the < 95% vs. ≥ 95% EOR for further survival com-
arison (GTR/NTR vs. PR). Karnofsky Performance Scale (KPS) was
easured before surgery and postoperatively at the end of the
ospitalization.
Statistical analyzes were performed with SAS 9.3. Fisher’s exact
est was used to compare EOR under surgical conditions (ioMRIgroup  vs. control group). Chi2 tests were performed on all other cat-
egorical parameters to compare the 4 subgroups deﬁned as: ioMRI
(GTR/NTR), ioMRI (PR), no ioMRI (GTR/NTR), no ioMRI (PR). Age
was compared between these 4 groups, using an analysis of vari-
ance (ANOVA). All tests were performed using a 2-sided type I error
of 0.05.
Overall survival was  considered as the time from surgery to
death/data analysis cut-off. The patients who  did not fall into
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Table 2
Evaluation of the initial resection by the senior surgeon (no additional resection
envisaged:  complete closure; additional resection very likely: partial closure), fol-
lowing strategy after the ioMRI and ﬁnal resection results.
Évaluation  de la résection initiale par le chirurgien senior (pas de résection additionnelle
prévue  : fermeture complète ; résection additionnelle très probable : fermeture partielle),
en fonction de la stratégie après l’ioMRI, et résultats ﬁnaux de la résection.
n = 55a Complete
closure (n = 31)
Partial closure
(n  = 24)
Reintervention (%) 3 (9.6) 11 (45.8)
GTR/NTR (%) 2 (6.4)b 7 (29.2)b
PR (%) 1 (3.2)b 4 (16.6)b
No reintervention (%) 28 (90.4) 13 (54.2)
GTR/NTR (%) 22  (71) 9  (37.5)
PR (%) 6 (19.4) 4 (16.7)
GTR: gross total resection; NTR: near total resection; PR: partial resection.
GTR : résection totale ; NTR : résection quasi-totale ; PR : résection partielle.
a Data is lacking for 1 patient.
a Donnée manquante pour 1 patient.
b
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rb Results after second resection.
Résultats après résection complémentaire.
his category were censored at the date of their last contact. The
aplan-Meier method was  used to estimate overall survival and
roduce the associated curves. A main endpoint, the effect of the
urgical procedure on overall survival, taking EOR into account as a
ovariate, was performed using a Cox Proportional Hazard model.
n order to assess further prognostic factors associated with overall
urvival, univariate and multivariate regressions (P ≤ 0.1 for factor
nclusion) were performed using Cox Proportional Hazard models.
Our main end points were the EOR and survival within each
ubgroup. Our secondary goal was to deﬁne indications for using
n ioMRI control.
.  Results
.1. Patients’ characteristics and adjuvant treatments
Age at surgery, sex, tumor location and side, as well as KPS
cores for each subgroup regarding the EOR variable and the sur-
ical condition are reported in Table 1. At the time of surgery, the
atients in the ioMRI group were aged 58.1 years ± 15.2, (range 14
o 82 years). In the control group, the mean age was  62.5 ± 10.9,
range 41 to 81 years). There were 37.5% female and 62.5% male
atients in the ioMRI group and 47.4% and 52.6% respectively in
he control group. None of the surgery in this series was  a sim-
le biopsy. After the intervention, the patients were referred to the
ncologist and radiotherapist for additional treatment. In the ioMRI
roup, 80.4% of patients received radiotherapy, 71.4% received con-
omitant temozolomide (TMZ) and 66.1% received adjuvant TMZ
ostoperatively. In the control group, 84.2% of patients received
adiotherapy, 73.3% received concomitant TMZ  and 60.5% received
djuvant TMZ. There were no signiﬁcant differences in any of these
haracteristics between the four main subgroups.
.2. Surgical procedure with ioMRI control
Among all interventions using ioMRI, only one ioMRI (1.8%)
as impossible to perform due to technical problems. For 4 other
atients (7.1%), the ioMRI procedure was possible but complex
problems of image fusion on neuronavigation, image acquisition,
able motorization dysfunction etc.).
In order to decide whether performing an ioMRI control was
seful, so that the surgeon could plan an additional surgical removal
uring the same anesthesia, we analyzed the type of closure (com-
lete or partial) made by the surgeons at the end of the ﬁrst
esection stage according to their impression of having reached aurgie 60 (2014) 143–150
maximal EOR or not (Table 2) (one element was missing so that the
total of patients for this analysis was 55). In 28 cases (90.4%) out
of 31 with a complete closure, the complete closure was  adequate:
in 22 cases (71%), the ioMRI revealed a GTR/NTR (17 GTR, 5 NTR)
and in 6 other cases (19.4%), PR was discovered but the surgeons
considered an additional resection to be too risky. However, in the
three (9.6%) remaining cases with a complete closure, the ioMRI
showed a signiﬁcant tumor residue and prompted the surgeon to
perform an additional resection during the same anesthesia. How-
ever, of these 3 cases, only 2 reached a NTR status and one remained
a PR.
Regarding the 24 patients with a partial temporary closure,
where a second stage was  considered (Table 2), an additional
resection was  carried out after the ioMRI control in only 11 cases
(45.8%): 4 cases (16.6%) remained a PR even after this additional
resection while in the other 7 cases (29%), the additional resection
permitted to reach a GTR/NTR status (5 GTR, 2 NTR). Regarding the
other 13 cases (54%) without a second surgical removal despite the
temporary partial closure, the ioMRI disclosed in 9 cases (37%) an
already GTR/NTR status (7 GTR, 2 NTR) and in 4 cases a PR sta-
tus (16.7%) for which an additional resection was considered too
risky. These 13 cases required to carry out a deﬁnitive closure of
the operating ﬁeld after the ioMRI.
3.3. Extent of resection
In  the ioMRI group, 36 patients (64.3%) reached a GTR/NTR dur-
ing the ﬁrst surgical step (see Fig. 1). Five of those with a NTR and 10
of the 20 with a PR (26.8%) had an immediate additional resection to
improve the EOR after the ioMRI. Of these 15 cases, 6 patients (40%)
reached a GTR, 4 (27%) a NTR and 5 (33%) remains in a PR status.
At the end, a total of 41 patients (73.2%) reached a GTR/NTR (53.6%
with a GTR and 19.6% with a NTR), whereas 15 patients (26.8%)
showed a PR. Thus using an ioMRI control improved the rate of
GTR/NTR of 8.9% and allowed ﬁve other patients (8.9%) initially with
a NTR to reach a GTR while remaining in the same group, i.e., the
GTR/NTR group. In fact, ioMRI in our series improved the rate of
resection by 17.8% (10/56) up to 73.2% of GTR/NTR. In the control
group, 20 patients (52%) had a GTR/NTR and 18 (48%) a PR. When
analyzing the EOR between the 2 main surgical groups (ioMRI vs.
control), a signiﬁcant difference was shown (P = 0.049, Fisher exact
test) (Table 1).
3.4.  Safety
The KPS scores in the ioMRI group were compared with the
scores in the control group and showed no difference (P = 0.335,
Chi2 test). Fifty-ﬁve patients (98.2%) in the ioMRI and 34 (89.5%) in
the control group had preoperative scores within 60–100. The post-
operative scores showed a decrease from preoperative KPS scores
in 33.9% of the patients from the ioMRI group and 26.3% of patients
in the control group. Nevertheless, an increase was reported for
12.5% and 13.2% of the patients respectively, while 53.6% and 55.3%
remained stable in those groups. Two  patients (3.6%) from the
ioMRI group died relatively soon after surgery (3 and 5 days) due to
a hemorrhage, one associated with an ischemic stroke. No mortality
or morbidity was  related to the use of the ioMRI.
3.5. Survival
Overall, 25.5% of the patients were alive at the time of the
analysis. The median survival durations were 12.24 months (95%
CI: 10.36–18.32) for the ioMRI group and 16.38 months (95% CI:
10.26–22.43) for the control group (as previously mentioned in the
ioMRI group two  patients died within the ﬁrst postoperative week
from a hemorrhagic complication). Nevertheless, the EOR covariate
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Fig. 2. Kaplan-Meier survival curves of the 94 patients divided into two  subgroups
deﬁned by: A. The extent of resection: survival in GTR/NTR group vs. PR group dif-
fers signiﬁcantly (P = 0.008 Log rank test, median 15.26 months 95% CI: 12.34–19.08
versus  10.26 months 95% CI: 6.64–15.82 respectively). GTR/NTR: gross total plus
near total resection; PR: partial resection. B. Adjuvant chemotherapy group vs. no
adjuvant chemotherapy group differs signiﬁcantly (P = 0.005 Log rank test, median
16.78 months 95% CI: 12.24–18.32 versus 7.70 months 95% CI: 5.53–15.26 respec-
tively). C. Sex: female and male groups differ signiﬁcantly (P < 0.001 Log rank test,
median 19.74 months 95% CI: 12.01–23.98 versus 12.24 months 95% CI: 10.26–13.75
respectively).  F: female; M:  male.
Courbes de survie de Kaplan-Meier pour les 94 patients divisés en deux sous-groupes en
fonction de : A. L’étendue de résection : la survie dans le groupe GTR/NTR vs PR diffère
signiﬁcativement (p = 0,008 Log Rank test, médiane 15,26 mois IC 95% : 12,34–19,08
versus  10,26 mois IC 95% : 6,64–15,82 respectivement). GTR/NTR : résection totale ouurgie 60 (2014) 143–150 147
alone showed a signiﬁcant effect on survival (P = 0.049, Wald test),
with higher risk of shorter survival for the patients with a PR
than a GTR/NTR (Hazard ratio = 1.6, 95% CI HR: 1.00–2.69), with a
median overall survival of 15.26 months (95% CI: 12.34–19.08) for
the GTR/NTR subgroup versus 10.26 months (95% CI: 6.64–15.82)
for the PR subgroup (Fig. 2). The effect of EOR on survival was
conﬁrmed, among other factors, by the uni- and multivariate
analyses mentioned below (Table 3).
To assess the effect of patients characteristics and non-surgical
treatment on survival, univariate analyses were performed using
Cox Proportional Hazard model for the following factors: age
at surgery, sex, preoperative and postoperative KPS scores and
additional treatment (concomitant chemotherapy or radiotherapy,
any adjuvant chemotherapy, or any combination of concomitant
or adjuvant treatment) (Table 4). Best ﬁtting model identiﬁed
4 independent predictors of overall survival: age, sex, EOR and
adjuvant chemotherapy factors (P < 0.001, Likelihood ratio test). In
this model, a signiﬁcant survival advantage was associated with a
GTR/NTR resection vs. PR (Hazard ratio = 1.8, 95% CI HR: 1.13–2.99,
P = 0.015), with adjuvant therapy (Hazard ratio = 1.9, 95% CI HR:
1.14–3.20, P = 0.014). Age and gender were also associated with a
signiﬁcant survival advantage (male vs. female: Hazard ratio = 1.86,
95% CI HR: 1.11–3.10, P = 0.019; age: Hazard ratio = 1.03 per unit
increase, 95% CI HR: 1.01–1.05, P < 0.001).
4.  Discussion
4.1. Extent of resection
GTR/NTR  rates could be increased using a high-ﬁeld ioMRI in
3 studies reporting a GTR/NTR rate of 89% [17] with GTR rates
approximately 40% [8,23]. These results are similar to our expe-
rience showing a GTR/NTR rate of 73.2% with a GTR rate of 53.6%.
A  previous comparison between surgery with and without intra-
operative imaging control was conducted using a 0.2T ioMRI in a
sample of 49 patients. A GTR rate of 96% was achieved in the ioMRI
group, whereas 68% of GTR was  observed in the control group [24].
These high rates of GTR could be explained by a less discriminative
ioMRI and the selection of patients with tumors in non-eloquent
areas.
A summary of the literature reporting on ioMRI in GBM resection
is presented in Table 5.
4.2.  Safety
As using an intraoperative imaging control could increase
the aggressiveness of the surgical procedure, we  compared the
morbidity rates between our both groups. In the ioMRI group,
perioperative mortality was 3.6% without a clear relation to the
EOR (one patient with NTR and one with PR) vs. none in the
control group. This was comparable to the rates reported in the
literature (between 0% and 6.5%) [8,11,13–17,22–25,30].  Even if it
has previously been reported that durable deﬁcits were not signif-
icantly higher in comparison with surgery without intraoperative
control [8,24], the morbidity rate seems to slightly increase in the
immediate postoperative course when using an intraoperative
imaging control [21]. This is not supported by the present study,
according to the KPS outcomes: despite the 2 postoperative deaths,
the difference was  not signiﬁcant between the 2 groups.
quasi-totale ; PR : résection partielle. B. Chemothérpie adjuvante ou non, diffère signi-
ﬁcativement (p = 0,005 Log Rank test, médiane 16,78 mois IC 95% : 12,24–18,32 versus
7,70 mois IC 95% : 5,53–15,26 respectivement). C. Sexe : femmes et hommes diffère sig-
niﬁcativement (p < 0,001 Log Rank test, médian 19,74 mois IC 95% : 12,01–23,98 versus
12,24 mois IC 95% : 10,26–13,75 respectivement). F : femme ; M : homme.
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Table 3
Survival analysis.
Analyse  de survie.
Characteristics ioMRI
GTR/NTR
n = 41
ioMRI
PR
n  = 15
No ioMRI
GTR/NTR
n  = 20
No ioMRI
PR
n  = 18
Total
n  = 94l
Survival status
Alive  13 (31.7%) 1 (6.7%) 8 (40.0%) 2 (11.1%) 24 (25.5%)
Deceased  28 (68.3%) 14 (93.3%) 12 (60.0%) 16 (88.9%) 70 (74.5%)
Kaplan-Meier  estimate of OS (months)
Median 13.75a 9.93 16.38 13.04 12.96
95%  CI (11.68–21.55) (2.66–11.74) (12.01–22.43) (3.95–23.72) (10.69–17.47)
Minimum  0.1 0.2 1.0 3.1 0.1
Maximum  48.5 44.3 78.0 37.6 78.0
Characteristics ioMRI
n = 56
No ioMRI
n  = 38
Total
n = 94
Survival status
Alive  14 (25.0%) 10  (26.3%) 24 (25.5%)
Deceased  42 (75.0%) 28 (73.7%) 70 (74.5%)
Kaplan-Meier  estimate of OS (months)
Median 12.24a 16.38 12.96
95%  CI (10.36–18.32) (10.26–22.43) (10.69–17.47)
Minimum  0.1 1.0 0.1
Maximum  48.5 78.0 78.0
Survival  rates
6  months 82.0% 83.8% 82.7%
1  year 50.3% 64.0% 55.9%
2  years 29.2% 20.8% 25.4%
3  years 15.5% 13.9% 14.4%
Global  test – P-value 0.147
P-values
MRI  effect 0.451
Hazard  ratio 1.2
95%  CI for Hazard ratio (0.74, 2.0)
EOR  0.049
Hazard  ratio 1.6
95%  CI for Hazard ratio (1.0, 2.7)
Hazard ratio is based on a Cox proportional Hazards model adjusted for EOR (GTR/NTR vs. PR). MRI  reference is no ioMRI; EOR reference is no GTR/NTR. P-values are based
on  a Cox proportional Hazards model adjusted for EOR. MRI–EOR interaction was tested but was  not signiﬁcant.
Le Hazard ratio est basé sur un modèle de Cox-risques proportionnels ajustés pour EOR (GTR/NTR vs PR). La référence IRM est « non IRM io » ; la référence EOR est « non GTR/NTR ». Les
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ealeurs de p sont basées sur un modèle de Cox-risques proportionnels ajustés pour EOS
a In this group, 2 patients died within the week following surgery due to an hem
Dans ce groupe, deux patients sont décédés dans la semaine suivant la chirurgie en ra.3. Survival
Our results demonstrate that ioMRI has no signiﬁcant impact
n survival probably due to the limited size of our population and
able 4
ni-  and multivariate regression analyses.
nalyses de régression uni- et multivariée.
Factor Value Univariate 
P-value Hazard ratio 
CHimioADJ No 0.051 1.64 
CHimioCONC No 0.249 1.37 
KPS  POSTop cat 0–50 0.031 1.92 
Missing 0.911 1.08 
KPS  PREop cat 0–50 0.202 0.47 
RxCONC  No 0.381 1.33 
Sex  M 0.009 1.94 
Age  0.001 1.03 
anyaddtrt  No 0.082 1.88 
anyconc  No 0.381 1.33 
mrigrp  No ioMRI 0.800 0.94 
resecgrp  PR 0.067 1.56 
nalysis performed using Cox Proportional Hazard model. EOR reference is no ioMRI; a
nclusion  if multivariate is set to P = 0.10.
’analyse a été effectuée à l’aide d’un modèle de Cox-risques proportionnels. La référence EOR
st « sexe féminin ». La limite supérieure pour inscription si multivariée est ﬁxée à p = 0,10.raction IRM–EOR a été testée mais n’était pas signiﬁcative.
e.
’une hémorragie.the  two deaths in the days following surgery, although EOR  was
clearly related to a longer survival, especially when other predictive
variables were favorable. Results reported in the literature sup-
port the importance of reaching a GTR/NTR to improve patients’
Multivariate
HR 95% CI P-value Hazard ratio HR 95% CI
(1.00–2.70) 0.014 1.91 (1.14–3.21)
(0.80–2.33)
(1.06–3.47)
(0.26–4.47)
(0.15–1.50)
(0.70–2.50)
(1.18–3.19) 0.019 1.86 (1.11–3.11)
(1.01–1.05) < 0.001 1.03 (1.01–1.05)
(0.92–3.82)
(0.70–2.50)
(0.58–1.52)
(0.97–2.51) 0.015 1.84 (1.13–2.99)
djuvant chemotherapy reference is yes; sex reference is female. Higher bound for
 est « non IRM io » ; la référence chimiothérapie adjuvante est « oui » ; la référence sexe
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Table  5
Summary of literature regarding GBM resection under ioMRI.
Résumé  de la littérature concernant la résection de GBM sous ioMRI.
Author, year Data collection MRI  ﬁeld Patient age [range] Number of patients Final resection
GTR (%) NTR (%) PR (%)
Bohinski et al., 2001 [16]b pr 0.3 [18–75] 22 14 (64) 8 (37)
Knauth  et al., 1999 [18]b NR 0.2 NR 41a 31 (76) 8 (19)
Lenaburg  et al., 2009 [20] re 0.2 NR 35 27 (77) 8 (23)
Nimsky  et al., 2002 [22] NR  0.2 [7–82] 32  7 (22) 25 (78)
Senft  et al., 2011 [24] pr (Lf) NR 24c 23 (96) 1 (4)
Wirtz  et al., 2000 [11] pr 0.2 [4–75] 66 37 (56) 29 (44)
Schneider  et al., 2005 [14]b pr 0.5 [39–75] 31 11 (35) 20 (65)
Trantakis  et al., 2002 [13] NR 0.5 NR 54 29 (54) 25 (46)
Hatiboglu  et al., 2009 [17] pr 1.5 [1–75] 27 24 (89) 3 (11)
Kuhnt  et al., 2011 [8] pr  1.5 NR 135 56 (41) 79  (59)
Nimsky  et al., 2006 [23] NR  1.5 [6–77] 57  23 (40) 34 (60)
Saint-Luc  (2013) re 3.0 [13–82] 56 41 (73.2) 15 (26.8)
GTR: gross total resection; Lf: low-ﬁeld; NTR: near total resection; NR: not reported; pr: prospective; PR: partial resection; re: retrospective.
GTR  : résection totale ; Lf : champ faible ; NTR : résection quasi-totale ; NR : non rapporté ; pr : prospectif ; PR : résection partielle ; re : rétrospectif.
a Uncertain outcomes were reported for 2 patients.
a Résultats incertains pour 2 patients.
b These authors deﬁned GTR as the resection of all enhancing tumor.
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aCes auteurs ont déﬁni une GTR comme la résection de toute la partie de la tumeur pre
c Two on 24 tumors were not GBM.
Deux sur 24 tumeurs n’étaient pas des GBM.
urvival. Patient survival probability was always longer in cases
f GTR [4,5,11,15]. Lacroix et al. observed a signiﬁcantly increased
urvival rate in patients who underwent a resection ≥ 98% (13 vs.
.8 months), as well as Kuhnt et al. In accordance with Schneider
t al., our results showed that patients with tumor resection ≥ 95%
ad a longer survival than patients with resection < 95%. The largest
eries (500 newly diagnosed GBM) was published by Sanai et al. and
howed that survival duration improved in correlation with greater
OR, supporting the importance of maximizing GBM resections.
.4.  Indication for using ioMRI
Some authors have reported that the best indications for using
n ioMRI in neurosurgery is improving glioma resection [28,31].
owever, as regards GBM resection in particular, we observed that
oMRI had different implications:
after  a complete closure (Table 2), ioMRI however led surgeons
to  perform an immediate second stage in 9.6% of cases stress-
ing  the potential ﬂawed EOR evaluation by the surgeons and the
usefulness  of the ioMRI;
in  cases of partial closure, ioMRI however prevented the surgeons
from  performing a second stage in 54.2% and was therefore clearly
useful  in preventing a risky additional resection;
in  cases of initial PR not continued by further resection (10/20,
Fig.  1), ioMRI could have not been performed. For these 10
cases,  the per-operative evaluation of an additional resection
was  considered associated with a too high permanent morbid-
ity.  When possible, these cases are now identiﬁed preoperatively
and,  depending on the patient’s desire to have no postoperative
morbidity, are not operated with an ioMRI;
regarding  the 15 patients (26.7%) submitted to an immediate sec-
ond step due to the analysis of the ioMRI, 6 reached a GTR, 4 a
NTR  and 5 remained in a PR status (5 showed already a NTR before
being  improved into GTR). Probably for the 5 patients remaining
with  a PR, a second ioMRI could have led to a third resection with
a  better EOR. However, the cost-effectiveness of such a strategy
remains  doubtful.
Based on this experience, the best indication for using an ioMRI
ppears to be when a GTR/NTR resection seems preoperativelye contraste.
possible associated with a low permanent morbidity. Three factors
should play a major role: the tumor location at distance from an
eloquent area, the surgeon’s experience and the patient desire.
4.5.  Limitations and strengths
Our  relatively small population and the partial retrospective
data collection are limitations of our report. However, the prospec-
tive collection of our intraoperative observations improves the
strength of this analysis.
5.  Conclusions
We  compared GBM resection using a high-ﬁeld ioMRI at 3.0T
with a control group without it. Using ioMRI improved the quality
of resection of 17.8% and increased the GTR/NTR rate of 8.9% up
to 73.2%, which is signiﬁcantly better than in the control group
(52%). Our survival results support the objective of reaching a GBM
resection of at least 95%. The best indication for using this type of
ioMRI control appears to be when a GTR/NTR seems preoperatively
possible with a low morbidity/mortality risk for the patient.
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